Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 178

Sort by

Sort Order Select

Journal Articles

MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis

Xinfang Yu, Wei Li, Qipan Deng, Haidan Liu, Xu Wang, Hui Hu, Ya Cao, Zijun Y. Xu-Monette, Ling Li, Mingzhi Zhang, Zhongxin Lu, Ken H. Young, Yong Li

Blood (2021) 137 (12): 1615–1627.

https://doi.org/10.1182/blood.2020004918

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting cereblon in AML

Steven Grant

Blood (2021) 137 (5): 584–586.

https://doi.org/10.1182/blood.2020009827

Published: 2021

Journal Articles

CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells

Blood (2021) 137 (5): 661–677.

https://doi.org/10.1182/blood.2020008676

Published: 2021

Includes: Supplemental data

Journal Articles

Unique Regulatory Pathways Dictate the Translational Program in Hematopoietic Stem and Progenitor Cells

Harold K. Elias, MD, Christina Spevak, PhD, Lavanya Kannan, PhD, Mohamed A.E. Ali, MD PhD, Gaelle H Martin, PhD, Shanmugapriya Selvaraj, MS, William S Eng, Guangjie Zhao, BS, Amanda Ernlund, PhD, Vinagolu Rajasekhar, PhD, Carolien M Woolthuis, MD PhD, Robert J Schneider, PhD, Christopher Y. Park, MD PhD

Blood (2019) 134 (Supplement_1): 1180.

https://doi.org/10.1182/blood-2019-131333

Published: 2019

Journal Articles

Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

Michael Amatangelo, Oliver Van Oekelen, MD MSc, Adeeb H Rahman, PhD, Alessandro Lagana, PhD, Sarah Gooding, FRCPath,MRCP,MBBChir, Hervé Avet-Loiseau, MD PhD, Udo Oppermann, PhD, William E Pierceall, PhD, Anjan Thakurta, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 1775.

https://doi.org/10.1182/blood-2019-126146

Published: 2019

Journal Articles

CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells

Antonia Lopez-Girona, Courtney G. Havens, Gang Lu, Emily Rychak, Derek Mendy, Bonny Gaffney, Christine Surka, Chin-Chun Lu, Mary Matyskiela, Gody Khambatta, Lilly Wong, Joshua Hansen, Daniel W. Pierce, Brian E. Cathers, James Carmichael

Blood (2019) 134 (Supplement_1): 1812.

https://doi.org/10.1182/blood-2019-124338

Published: 2019

Journal Articles

CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma

Lilly Wong, Rama Krishna Narla, Jim Leisten, Daniel Bauer, Matthew Groza, Bonny Gaffney, Courtney G. Havens, Justin Choi, Jack Houston, Antonia Lopez-Girona, Joshua Hansen, Brian E. Cathers, James Carmichael, Daniel W. Pierce

Blood (2019) 134 (Supplement_1): 1815.

https://doi.org/10.1182/blood-2019-124345

Published: 2019

Journal Articles

Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas

Lorena Fontan, PhD, John Hatcher, PhD, David Scott, Qi Qiao, Ilkay Us, Guangyan Du, Matthew Durant, Jimmy Wilson, Hao Wu, PhD, Nathanael Gray, Ari Melnick, MD

Blood (2019) 134 (Supplement_1): 2073.

https://doi.org/10.1182/blood-2019-130666

Published: 2019

Journal Articles

RFWD2 Induces Cellular Proliferation and Proteasome Inhibitor Resistance By Mediating p27 Ubiqutinaiton in Multiple Myeloma

Ye Yang, PhD, Mengjie Guo, Chunyan Gu

Blood (2019) 134 (Supplement_1): 3068.

https://doi.org/10.1182/blood-2019-127888

Published: 2019

Journal Articles

UAF1 DNA Binding Activity Is Critical for RAD51-Mediated Homologous DNA Pairing

Fengshan Liang, PhD, Adam S Miller, PhD, Carolilne Tang, Patrick Sung, PhD, Gary M. Kupfer, MD

Blood (2019) 134 (Supplement_1): 2497.

https://doi.org/10.1182/blood-2019-130435

Published: 2019

Journal Articles

Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Jinhong Fan, Hongbin Wang, Suzana Couto, Tsun-Wen Sheena Yao, Geoffrey L. Uy, MD, Amer M. Zeidan, MBBS, MHS, Mark D. Minden, Pau Montesinos, Daniel J. DeAngelo, Jessica K. Altman, Jamie Koprivnikar, MD, Paresh Vyas, MD PhD, Yngvar Fløisand, María Belén Vidriales, Bjørn Tore Gjertsen, Tonia J. Buchholz, Michael Pourdehnad, Daniel W. Pierce

Blood (2019) 134 (Supplement_1): 2547.

https://doi.org/10.1182/blood-2019-124291

Published: 2019

Journal Articles

Oncogenic Mechanisms of CBL E3 Ubiquitin Ligase Mutations in Myeloid Malignancies

Roger Belizaire, MD PhD, Sebastian Koochaki, BS, MS, Namrata Udeshi, PhD, Alexis Vedder, BS, Lei Sun, Monica Schenone, PhD, Steven Carr, PhD, Eric Padron, MD, Benjamin L. Ebert, MD PhD

Blood (2019) 134 (Supplement_1): 563.

https://doi.org/10.1182/blood-2019-122503

Published: 2019

Journal Articles

Elucidating the Mechanism of Action of CC-90009, a Novel Cereblon E3 Ligase Modulator, in AML Via Genome-Wide CRISPR Screen

Gang Lu, Christine Surka, Chin-Chun Lu, In Sock Jang, PhD, Kai Wang, PhD, Mark Rolfe, PhD

Blood (2019) 134 (Supplement_1): 405.

https://doi.org/10.1182/blood-2019-125492

Published: 2019

Journal Articles

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

Blood (2019) 134 (Supplement_1): 318.

https://doi.org/10.1182/blood-2019-130549

Published: 2019

Journal Articles

Disrupting GRINL1A Association with Cereblon Accelerates IKZF1/3 Degradation and IMiD Killing of Mantle Cell Lymphoma Cells By CDK4/6 Inhibition

Nicole Zhao, Maurizio Di Liberto, PhD, Olivier Elemento, PhD, Selina Chen-Kiang, PhD, Xiangao Huang, PhD

Blood (2019) 134 (Supplement_1): 299.

https://doi.org/10.1182/blood-2019-128927

Published: 2019

Journal Articles

Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

Blood (2019) 134 (Supplement_1): 232.

https://doi.org/10.1182/blood-2019-123966

Published: 2019

Journal Articles

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Yonghan He, MD, Raphael Koch, Vivekananda Budamagunta, Dongwen Lv, Sajid Khan, Xuan Zhang, Janet S Wiegand, Guangrong Zheng, David M. Weinstock, MD, Daohong Zhou

Blood (2019) 134 (Supplement_1): 303.

https://doi.org/10.1182/blood-2019-125820

Published: 2019

Journal Articles

Interactome of Aiolos/Ikaros in Diffuse Large B-Cell Lymphoma (DLBCL) Reveals Novel Combination of Cereblon Modulators (CELMoD) and Histone Deacetylase (HDAC) Inhibitors

Patrick R. Hagner, PhD, Hsiling Chiu, MS, Vivek S. Chopra, PhD, Martino S. Colombo, PhD, Nisha Patel, PhD, Maria Ortiz, Remco S. Loos, PhD, Fadi Towfic, PhD, Michelle Waldman, MS, Anita K Gandhi

Blood (2019) 134 (Supplement_1): 306.

https://doi.org/10.1182/blood-2019-126681

Published: 2019

Journal Articles

Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies

Fred Csibi, Nan Ji, PhD, Bin Yang, Karen Yuan, Michele Mayo, Haojing Rong, PhD, Scott Rusin, Kirti Sharma, Christine Loh, PhD, Henry Li, PhD, Sharon Townson, Jesse Chen, PhD, Hari Kamadurai, PhD, Duncan Walker, PhD, Jared Gollob, PhD MD, Nello Mainolfi, PhD

Blood (2019) 134 (Supplement_1): 3803.

https://doi.org/10.1182/blood-2019-128981

Published: 2019

Journal Articles

CRISPR-Cas9 Screen Identifies XPO7 As a Potential Therapeutic Target for TP53 -Mutated AML

Yuichiro Semba, MD PhD, Takuji Yamauchi, MD PhD, Fumihiko Nakao, MD, Jumpei Nogami, PhD, Matthew C. Canver, MD PhD, Luca Pinello, PhD, Daniel E. Bauer, MD PhD, Koichi Akashi, MD PhD, Takahiro Maeda, MD PhD

Blood (2019) 134 (Supplement_1): 3784.

https://doi.org/10.1182/blood-2019-129623

Published: 2019

NARROW

MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis

Targeting cereblon in AML

CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells

Unique Regulatory Pathways Dictate the Translational Program in Hematopoietic Stem and Progenitor Cells

Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients

CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells

CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma

Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas

RFWD2 Induces Cellular Proliferation and Proteasome Inhibitor Resistance By Mediating p27 Ubiqutinaiton in Multiple Myeloma

UAF1 DNA Binding Activity Is Critical for RAD51-Mediated Homologous DNA Pairing

Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Oncogenic Mechanisms of CBL E3 Ubiquitin Ligase Mutations in Myeloid Malignancies

Elucidating the Mechanism of Action of CC-90009, a Novel Cereblon E3 Ligase Modulator, in AML Via Genome-Wide CRISPR Screen

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

Disrupting GRINL1A Association with Cereblon Accelerates IKZF1/3 Degradation and IMiD Killing of Mantle Cell Lymphoma Cells By CDK4/6 Inhibition

Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Interactome of Aiolos/Ikaros in Diffuse Large B-Cell Lymphoma (DLBCL) Reveals Novel Combination of Cereblon Modulators (CELMoD) and Histone Deacetylase (HDAC) Inhibitors

Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies

CRISPR-Cas9 Screen Identifies XPO7 As a Potential Therapeutic Target for TP53 -Mutated AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only